Ligand Pharmaceuticals Inc (LGND) stock
LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30433% above fair value
$293.81−7.90 (-2.62%)
Close on Nov 17, 2026Market cap $5.88BP/E 128.3Yield –
Ligand Pharmaceuticals profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Ligand Pharmaceuticals's profit margin for the twelve months ending Sep 30, 2026 was 20.3%. For fiscal 2025 it was 46.4%, against -2.4% the year before. The highest annual figure on record is 523.2% in fiscal 2019.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 46.4% | +48.8 |
| FY2024 | Dec 31, 2024 | -2.4% | −42.1 |
| FY2023 | Dec 31, 2023 | 39.7% | +56.7 |
| FY2022 | Dec 31, 2022 | -17.0% | −40.7 |
| FY2021 | Dec 31, 2021 | 23.7% | +25.5 |
| FY2020 | Dec 31, 2020 | -1.8% | −525.0 |
| FY2019 | Dec 31, 2019 | 523.2% | +466.2 |
| FY2018 | Dec 31, 2018 | 57.0% | +48.1 |
| FY2017 | Dec 31, 2017 | 8.9% | +10.4 |
| FY2016 | Dec 31, 2016 | -1.5% | −321.1 |
| FY2015 | Dec 31, 2015 | 319.6% | +301.0 |
| FY2014 | Dec 31, 2014 | 18.6% | −4.7 |
| FY2013 | Dec 31, 2013 | 23.3% | +25.0 |
| FY2012 | Dec 31, 2012 | -1.7% | −34.0 |
| FY2011 | Dec 31, 2011 | 32.3% | +76.4 |
| FY2010 | Dec 31, 2010 | -44.1% | −39.1 |
| FY2009 | Dec 31, 2009 | -5.0% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -36.2% | −137.7 |
| Q2 FY2026 | Jun 30, 2026 | 76.2% | +66.0 |
| Q1 FY2026 | Mar 31, 2026 | -25.8% | +67.8 |
| Q4 FY2025 | Dec 31, 2025 | 75.1% | +147.7 |
| Q3 FY2025 | Sep 30, 2025 | 101.6% | +115.4 |
| Q2 FY2025 | Jun 30, 2025 | 10.2% | +135.2 |
| Q1 FY2025 | Mar 31, 2025 | -93.6% | −371.7 |
| Q4 FY2024 | Dec 31, 2024 | -72.6% | −137.3 |
| Q3 FY2024 | Sep 30, 2024 | -13.8% | +17.4 |
| Q2 FY2024 | Jun 30, 2024 | -125.0% | −133.7 |
| Q1 FY2024 | Mar 31, 2024 | 278.1% | +182.7 |
| Q4 FY2023 | Dec 31, 2023 | 64.7% | +99.4 |
| Q3 FY2023 | Sep 30, 2023 | -31.3% | −31.9 |
| Q2 FY2023 | Jun 30, 2023 | 8.7% | +10.5 |
| Q1 FY2023 | Mar 31, 2023 | 95.4% | +137.5 |
| Q4 FY2022 | Dec 31, 2022 | -34.7% | −25.1 |
| Q3 FY2022 | Sep 30, 2022 | 0.7% | −22.3 |
| Q2 FY2022 | Jun 30, 2022 | -1.8% | −40.7 |
| Q1 FY2022 | Mar 31, 2022 | -42.1% | −81.0 |
| Q4 FY2021 | Dec 31, 2021 | -9.6% | −17.8 |
| Q3 FY2021 | Sep 30, 2021 | 23.0% | +39.0 |
| Q2 FY2021 | Jun 30, 2021 | 39.0% | −14.4 |
| Q1 FY2021 | Mar 31, 2021 | 38.9% | +111.6 |
| Q4 FY2020 | Dec 31, 2020 | 8.2% | +35.5 |
| Q3 FY2020 | Sep 30, 2020 | -16.0% | +45.5 |
| Q2 FY2020 | Jun 30, 2020 | 53.3% | +111.0 |
| Q1 FY2020 | Mar 31, 2020 | -72.8% | −1605.1 |
| Q4 FY2019 | Dec 31, 2019 | -27.3% | +44.0 |
| Q3 FY2019 | Sep 30, 2019 | -61.5% | −209.0 |
| Q2 FY2019 | Jun 30, 2019 | -57.7% | −139.0 |
| Q1 FY2019 | Mar 31, 2019 | 1532.4% | +1451.7 |
| Q4 FY2018 | Dec 31, 2018 | -71.3% | +0.0 |
| Q3 FY2018 | Sep 30, 2018 | 147.5% | +0.0 |
| Q2 FY2018 | Jun 30, 2018 | 81.3% | +0.0 |
| Q1 FY2018 | Mar 31, 2018 | 80.6% | +0.0 |
| Q4 FY2017 | Dec 31, 2017 | -71.3% | −63.1 |
| Q3 FY2017 | Sep 30, 2017 | 147.5% | – |
| Q2 FY2017 | Jun 30, 2017 | 81.3% | – |
| Q1 FY2017 | Mar 31, 2017 | 80.6% | – |
| Q4 FY2016 | Dec 31, 2016 | -8.2% | – |
See a number that looks wrong?